Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Enalapril. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE known ✓ | P12821 | 14/20 | 0.91 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 0.91 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | USP2 | O75604 | 1/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.63 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Enalapril SCHEMBL20817249 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2ACELMNAABCB11MEN1 | |
| Enalapril SCHEMBL10 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2ACELMNAABCB11MEN1 | |
| Enalapril SCHEMBL9 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2ACELMNAABCB11MEN1 | |
| Enalapril SCHEMBL6155137 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2ACELMNAABCB11MEN1 | |
| Enalapril SCHEMBL10390115 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2ACELMNAABCB11MEN1 | |
| Enalapril SCHEMBL1650291 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2ACELMNAABCB11MEN1 | |
| Enalapril SCHEMBL308603 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2ACELMNAABCB11MEN1 | |
| Enalapril SCHEMBL825430 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2ACELMNAABCB11MEN1 | |
| Enalapril SCHEMBL9019924 | 0.99 | SMN1; SMN2 (0.98) | SMN1; SMN2ACELMNAABCB11MEN1 | |
| Enalapril SCHEMBL9019927 | 0.99 | SMN1; SMN2 (0.98) | SMN1; SMN2ACELMNAABCB11MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102482256-B | N-substituted cyclic amino derivatives | DAINIPPON SUMITOMO PHARMA CO | 2014-11-26 | — | — | CN | disclosed |
| US-8658639-B2 | N-substituted-cyclic amino derivative | DAINIPPON SUMITOMO PHARMA CO., LTD (JP) | 2014-02-25 | — | — | US | disclosed |
| CN-102482256-A | N-substituted cyclic amino derivatives | DAINIPPON SUMITOMO PHARMA CO | 2012-05-30 | — | — | CN | disclosed |
| US-20120122773-A1 | N-SUBSTITUTED-CYCLIC AMINO DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
| EP-2447264-A1 | N-SUBSTITUTED-CYCLIC AMINO DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2012-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122773-A1 | N-SUBSTITUTED-CYCLIC AMINO DERIVATIVE | REN, AGTR1, AGTR2 | ACE 6/4885SMN1; SMN2 4274/4885LMNA 1723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.